The mRNA cancer vaccines now in development come with large economic benefits
Eugene/Getty Images
In August 2025, the US made a significant decision to cut half a billion dollars in funding for vaccine development, which had potential repercussions on the benefits of mRNA cancer vaccines. The estimated value of these benefits could reach up to $75 billion annually in the US, as indicated by Alison Galvani and her team at Yale University.
Galvani and her colleagues emphasized the importance of these mRNA vaccines in advancing therapeutic progress by targeting proteins on cancerous cells to enhance the body’s immune response. The ability to personalize these vaccines according to individual cancer types adds to their effectiveness and efficiency.
By analyzing 32 ongoing mRNA cancer vaccine trials in the US, the researchers narrowed down to 11 promising trials and projected the potential increase in life expectancy over a three-year period if these vaccines are administered to eligible individuals annually. The economic value of preventing nearly 50,000 deaths through these vaccines was calculated to be $75 billion.
However, the reduction in federal investment in mRNA vaccine technology poses a risk of forfeiting these substantial benefits, Galvani and her team warned. Oliver Watson from Imperial College London, who has conducted similar studies on vaccine benefits, noted that the estimated economic value could be even higher if extended over multiple cohorts and a longer timeframe.
It is essential to consider the long-term implications and value of mRNA cancer vaccines, especially in the context of advancing cancer treatment and healthcare economics. The potential economic benefits and life-saving impact of these vaccines underscore the significance of continued investment and research in this field.
Topics:
